Hjem › Eggstokkreft › Texas › Fort Worth
Kliniske studier for Eggstokkreft i Fort Worth, TX
17 studier for Eggstokkreft søker deltakere på steder i og rundt Fort Worth (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
RekruttererFase 2/3
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
A Study of PHST001 in Advanced Solid Tumors
RekruttererFase 1
- START Center for Cancer Research - Texas, Fort Worth
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RekruttererFase 1
- START Center for Clinical Research, Fort Worth
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RekruttererFase 2
- Texas Oncology - Fort Worth Cancer Center /ID# 275043, Fort Worth
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
RekruttererFase 3
- Texas Oncology - DFW ( Site 8005), Fort Worth
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
RekruttererFase 2
- Texas Oncology - Fort Worth Cancer Center /ID# 277989, Fort Worth
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RekruttererFase 3
- Jps Health Network, Fort Worth
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
RekruttererFase 1/2
- Start Dfw, Fort Worth
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekruttererFase 1
- Start - Dfw, Fort Worth
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RekruttererFase 3
- Texas Oncology - DFW ( Site 8001), Fort Worth
Study of NTB-928 in R/R OC
RekruttererFase 1
- Start Ccbd, Llc, Fort Worth
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
RekruttererFase 1
- Xencor Investigative Site, Fort Worth
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
RekruttererFase 3
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekruttererFase 1/2
- USOR Texas Oncology, Fort Worth
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
RekruttererFase 2/3
- Texas Oncology Paris, Fort Worth
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
RekruttererFase 1
- START Dallas, Fort Worth
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RekruttererFase 2
- SCRI - Texas Oncology, Fort Worth
Eggstokkreft-studier i andre byer
- Houston, TX89 studier
- New York City, NY69 studier
- Boston, MA61 studier
- Los Angeles, CA50 studier
- Nashville, TN49 studier
- Arlington, VA46 studier
- Philadelphia, PA44 studier
- Columbus, OH39 studier
- St. Louis, MO38 studier
- Chicago, IL36 studier
- San Antonio, TX31 studier
- Cleveland, OH30 studier
Andre studier i Fort Worth
- Ikke-småcellet lungekreft18 studier
- Endometriekreft12 studier
- Brystkreft12 studier
- Kreft (alle typer)9 studier
- Prostatakreft9 studier
- Tripelnegativ brystkreft7 studier
- Makuladegenerasjon7 studier
- Ulcerøs kolitt7 studier
- Nyrekreft (nyrecellekarcinom)7 studier
- Hjertesvikt7 studier
- Metastatisk kreft7 studier
- Kolorektal kreft7 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.